Vaxcyte's Chief Technical Ops Officer Sells Shares

1 week ago 9

Lawrence Rothman, CFA, The Motley Fool

Sat, January 3, 2026 astatine 9:37 AM CST 5 min read

The CTO sold 9,743 shares.
The merchantability represented 28.9% of Dhaliwal's holdings.
These 10 stocks could mint the adjacent question of millionaires ›

Focused connected next-generation vaccines for bacterial diseases, this biotech conscionable reported a notable insider merchantability amid a challenging year.

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte (NASDAQ:PCVX), disposed of 9,743 shares successful an open-market merchantability valued astatine astir $454,891 according to the SEC Form 4 filing.

Metric

Value

Shares sold (direct)	9,743
Transaction value	~$454,890.93
Post-transaction shares (direct)	23,928
Post-transaction worth (direct ownership)	~$1,111,694.88

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($46.69); post-transaction worth based connected Jan. 2 marketplace adjacent ($46.46).

How important was this merchantability successful narration to Dhaliwal's anterior holdings?
The transaction reduced nonstop ownership by 28.9%, shifting Dhaliwal's involvement from 33,671 shares to 23,928 shares, with nary remaining indirect exposure.
Were immoderate derivative, trust, oregon administrative mechanisms involved?
This was a straightforward open-market merchantability of communal banal with nary derivative exercise, trust, oregon administrative withholdings reported successful the filing.

Metric

Value

Price (as of marketplace adjacent Jan. 2, 2026)	$46.46
Market capitalization	$6.08 billion
Net income (TTM)	-$657.20 million
1-year terms change	-44.20%

* 1-year show calculated utilizing Jan. 2 arsenic the notation date.

Vaxcyte is simply a clinical-stage biotechnology institution specializing successful the improvement of next-generation macromolecule vaccines to code unmet aesculapian needs successful bacterial infectious illness prevention. With a pipeline led by VAX-24, the institution leverages precocious conjugation and macromolecule engineering technologies to grow vaccine sum and code antibiotic resistance. The strategy centers connected innovation successful vaccine plan and a absorption connected diseases with important planetary wellness impact, positioning it arsenic a differentiated subordinate successful the vaccine improvement landscape.

Develops clinical-stage vaccines, including VAX-24 for pneumococcal disease, VAX-XP for emerging strains, VAX-A1 for Group A Strep, and VAX-PG for periodontitis.
Operates a biotechnology concern exemplary focused connected research, development, and eventual commercialization of caller protein-based vaccines targeting bacterial infectious diseases.
Targets healthcare providers, hospitals, and nationalist wellness agencies seeking precocious vaccine solutions for infectious illness prevention.